CVS Caremark is adding Zepbound, Eli Lilly’s obesity drug, back to its commercial insurance plan formularies, more than a year after it stopped covering it in favor of Novo Nordisk’s Wegovy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results